Shares of Applied Genetic Technologies Corp. (NASDAQ:AGTC) saw strong trading volume on Monday . 85,291 shares traded hands during mid-day trading, an increase of 18% from the previous session’s volume of 72,085 shares.The stock last traded at $13.26 and had previously closed at $13.22.

A number of research analysts have recently issued reports on the stock. Cantor Fitzgerald restated a “buy” rating and issued a $32.00 price target on shares of Applied Genetic Technologies Corp. in a research report on Wednesday, June 22nd. Wedbush reaffirmed an “outperform” rating and issued a $36.00 price objective on shares of Applied Genetic Technologies Corp. in a report on Tuesday, May 10th. Wells Fargo & Co. reaffirmed a “buy” rating on shares of Applied Genetic Technologies Corp. in a report on Tuesday, May 10th. Finally, Zacks Investment Research raised shares of Applied Genetic Technologies Corp. from a “hold” rating to a “buy” rating and set a $15.00 price objective on the stock in a report on Wednesday, May 11th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company. Applied Genetic Technologies Corp. has an average rating of “Buy” and a consensus price target of $26.00.

The company’s market cap is $239.30 million. The company’s 50-day moving average is $15.12 and its 200-day moving average is $15.10.

An institutional investor recently raised its position in Applied Genetic Technologies Corp. stock. Jennison Associates LLC increased its position in Applied Genetic Technologies Corp. (NASDAQ:AGTC) by 0.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 677,610 shares of the company’s stock after buying an additional 3,248 shares during the period. Jennison Associates LLC owned about 3.76% of Applied Genetic Technologies Corp. worth $13,823,000 as of its most recent SEC filing.

Applied Genetic Technologies Corp is a United States-based clinical stage biotechnology company. The Company develops gene therapy products for the treatment of inherited and acquired diseases. Its products are used to treat Alpha One Antitrypsin Deficiency (Alpha-1), a respiratory disease caused by deficiencies in the tissue protective protein alpha one antitrypsin; and Lebers congenital amaurosis, an inherited condition causing early blindness.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.